5-Methoxy-3,4-dihydronaphthalene-1-carbonitrile | 98218-37-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 5-Methoxy-3,4-dihydronaphthalene-1-carbonitrile
• 英文别名: 3,4-dihydro-5-methoxy-1-naphthalenecarbonitrile；1-cyano-5-methoxy-3,4-dihydronaphthalene；5-Methoxy-3,4-dihydronaphthalene1-carbonitrile；1-Cyano-5-methoxy-(3,4-dihydronaphthalene)
• CAS: 98218-37-2
• 化学式: C₁₂H₁₁NO
• 分子量: 185.225
• InChiKey: WTFOOOFBFWOMPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  33
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-Methoxy-3,4-dihydronaphthalene-1-carbonitrile 在 RaNi 氨 、 氢气 作用下， 以 甲醇 为溶剂， 生成 N-<(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)methyl>amine
  参考文献：
  名称：

  Structure−Activity Studies for a Novel Series of N-(Arylethyl)-N-(1,2,3,4-tetrahydronaphthalen-1-ylmethyl)-N-methylamines Possessing Dual 5-HT Uptake Inhibiting and α₂-Antagonistic Activities

  摘要：

  In search of an alpha(2)-antagonist/5-HT uptake inhibitor as a potential new class of antidepressant with a more rapid onset of action, compound 3 was prepared and observed to possess high affinity for the alpha(2)-receptor (K-i = 6.71 nM) and the 5-HT uptake site (20.6 nM). A series of tertiary amine analogs of 3 were synthesized and assayed for their affinity at both the alpha(2)-receptor and the 5-HT uptake site. The structure-activity relationship reveals that a variety of structural modifications to the arylethyl fragment are possible with retention of this dual activity. On the tetralin portion, 5-OMe substitution and the (R) stereochemistry at C-l are optimal with alternate substitutions producing compounds retaining high affinity for the alpha(2)-receptor but lacking affinity for the 5-HT uptake site. Data for several rigidified 5-O-alkyl analogs suggests that the favored orientation of the oxygen lone pairs may be away from the g-position of the tetralin.

  DOI：

  10.1021/jm960723m
• 作为产物：
  描述：

  5-甲氧基-3,4-二氢-2H-1-萘酮 在 AlCl₃ 吡啶 、 三氯氧磷 作用下， 以 苯 为溶剂， 以54 g (73%)的产率得到5-Methoxy-3,4-dihydronaphthalene-1-carbonitrile
  参考文献：
  名称：

  Tetrahydro-6,7-dimethoxy-1H-benz[e]isoinodolines useful in the treatment

  摘要：

  本公开涉及的是由以下式表示的四氢-苯并[e]异喹啉：其中R、R.sub.1和R.sub.2分别选自氢、1至4个碳原子的低碳烷基、羟基、1至3个碳原子的低碳氧烷基、烯丙氧基、苄氧基、苯甲酰氧基、硫甲基、卤素、t为0或1、n为0至5、R.sub.11和R.sub.14分别选自氢、卤素、羟基、1至4个碳原子的低碳烷基、1至3个碳原子的低碳氧烷基或氨基；或R和R.sub.1，或R.sub.1和R.sub.2可以结合形成亚甲二氧桥或乙烯二氧桥；但R、R.sub.1或R.sub.2中至少有一个必须不是氢，且当R、R.sub.1或R.sub.2中的另外一个是氢时，R、R.sub.1或R.sub.2中的两个必须不是7和8位置的甲氧基；R.sub.3是氢、1至4个碳原子的低碳烷基、1至4个碳原子的卤素取代的低碳烷基、1至4个碳原子的氨基取代的低碳烷基、氨基取代的芳基烷基、烯丙基、硫代低碳烷基、低碳醇、或其中R.sub.12和R.sub.13分别选自氢、羟基、氨基、1至3个碳原子的低碳氧烷基，s为1至3；或m为0、1或2、p为0或1、R.sub.7为氢或1至4个碳原子的低碳烷基，R.sub.8和R.sub.9分别选自氢、羟基、甲氧基、1至4个碳原子的低碳烷基或卤素，或R.sub.8和R.sub.9可以结合形成亚甲二氧桥或乙烯二氧桥；或以下式的1,4-苯并二氧杂环己烷：其中q为1、2或3，R.sub.10为氢、甲氧基、氨基或卤素；以及其药学上可接受的盐。

  公开号：

  US04618683A1

文献信息

• Naphthyloxy acetic acid derivatives and a pharmaceutical composition comprising them as an active ingredient
  申请人：Ono Pharmaceutical Co., Ltd.

  公开号：US06335366B2

  公开（公告）日：2002-01-01

  The naphthyloxyacetic acid derivatives of the formula (I) wherein A is H, -(alkylene)COOR1, -(alkylene)CONR2R3, -(alkylene)OH, -(alkylene)tetrazole, -(alkylene)CN; E is single bond or alkylene; G is —S—, —SO—, —SO2—, —O— or —NR4—; L is alkylene, —(CH2)m—CH═CH—(CH2)n— or —(CH2)x—CH(OH)—(CH2)y—; M is phenyl, phenyl(thio, oxy, amino), diphenylmethyl, diphenylmethyl(thio, oxy, amino), and pharmaceutical composition comprising them as an active ingradient. The compounds of the formula (I) can combine PGE2 receptor and exhibit the activity to antagonize or agonize for PGE2 receptor. Therefore, they are useful as anti-hyperlipemia, for the prevention of abortion, for analgesics, as antidiarrheals, sleep inducer, diuretic, anti-diabetes, abortient, cathartics, antiulcer, anti-gastritis or antihypertensive etc.

  式(I)的萘氧乙酸衍生物 其中A为H，-(烷基)COOR1，-(烷基)CONR2R3，-(烷基)OH，-(烷基)四唑，-(烷基)CN；E为单键或烷基；G为—S—，—SO—，—SO2—，—O—或—NR4—；L为烷基，—(CH2)m—CH═CH—(CH2)n—或—(CH2)x—CH(OH)—(CH2)y—；M为苯基，苯基(硫、氧、氨基)，二苯甲基，二苯甲基(硫、氧、氨基)，以及包含它们作为活性成分的药物组合物。式(I)的化合物可以结合PGE2受体，并表现出对PGE2受体的拮抗或激动活性。因此，它们可用作抗高脂血症、预防流产、镇痛剂、止泻药、催眠剂、利尿剂、抗糖尿病药、引产剂、泻药、抗溃疡药、抗胃炎药或降压药等。
• Adrenergic amidines
  申请人：Abbott Laboratories

  公开号：US04634705A1

  公开（公告）日：1987-01-06

  Disclosed herein are adrenergic compounds represented by the formula ##STR1## wherein m is 0, 1 or 2; R.sub.1, R.sub.2, R.sub.3 and R.sub.7 are taken from the group consisting of hydrogen, hydroxy, loweralkyl, loweralkoxy, halo, amino, acetamido or NHSO.sub.2 R wherein R is taken from the group consisting of hydrogen or loweralkyl, provided that R.sub.1, R.sub.2, R.sub.3 and R.sub.7 cannot simultaneously be hydrogen or halo, and provided that when one of R.sub.1, R.sub.2, R.sub.3 and R.sub.7 is halo, the others cannot simultaneously be hydrogen and when two of R.sub.1, R.sub.2, R.sub.3 and R.sub.7 are halo, the other two cannot simultaneously be hydrogen and provided that R.sub.1 and R.sub.7 cannot simultaneously be methoxy each when R.sub.2 and R.sub.3 are hydrogen; R.sub.1 and R.sub.2 or R.sub.2 and R.sub.3 or R.sub.3 and R.sub.7 taken together can form a methylenedioxy or ethylenedioxy bridge; or R.sub.1 and R.sub.2 or R.sub.2 and R.sub.3 or R.sub.3 and R.sub.7 taken together with the aromatic ring can form a benzimidazole or indole bridge; and R.sub.4 and R.sub.5 are hydrogen or taken together form a closed ring of the formula ##STR2## wherein n is 1 or 2, and the combined solid and dashed line represents a single or double bond when n is 1, and R.sub.6 is taken from the group consisting of hydrogen or loweralkyl, and the pharmaceutically acceptable salts thereof.

  本公开涉及的肾上腺素类化合物由以下式表示：其中m为0、1或2；R.sub.1、R.sub.2、R.sub.3和R.sub.7取自氢、羟基、较低烷基、较低烷氧基、卤素、氨基、乙酰胺基或NHSO.sub.2 R的群，其中R取自氢或较低烷基，但要求R.sub.1、R.sub.2、R.sub.3和R.sub.7不能同时为氢或卤素，且当R.sub.1、R.sub.2、R.sub.3和R.sub.7中的一个为卤素时，其他的不能同时为氢，当R.sub.1、R.sub.2、R.sub.3和R.sub.7中有两个为卤素时，其他两个不能同时为氢，而且当R.sub.1和R.sub.7同时为甲氧基时，R.sub.2和R.sub.3为氢；R.sub.1和R.sub.2或R.sub.2和R.sub.3或R.sub.3和R.sub.7结合在一起可以形成甲二氧基或乙二氧基桥；或者R.sub.1和R.sub.2或R.sub.2和R.sub.3或R.sub.3和R.sub.7与芳香环结合在一起可以形成苯并咪唑或吲哚桥；R.sub.4和R.sub.5为氢或结合在一起形成下式的闭环：其中n为1或2，组合的实线和虚线代表单键或双键，当n为1时，R.sub.6取自氢或较低烷基，以及其药用可接受的盐。
• 1-aminomethyl-1,2,3,4-tetrahydronaphthalenes
  申请人：Abbott Laboratories

  公开号：US05128362A1

  公开（公告）日：1992-07-07

  The present invention provides compounds of the formula ##STR1## or a pharmaceutically acceptable salt thereof wherein R.sub.1 is selected from hydrogen, halo, lower alkyl, lower alkoxy, or thioalkoxy; and R.sub.2 is lower alkoxy; or R.sub.1 and R.sub.2 together form a methylenedioxy or ethylenedioxy ring; R.sub.3 and R.sub.4 are independently selected from hydrogen, hydroxy, lower alkyl, lower alkoxy, lower alkylthio, (lower alkyl)amino, (lower alkylsulfonyl)amino, and halo; and R.sub.7 is selected from the group consisting of 2- or 3-thienyl, 2- or 3-furyl, and ##STR2## where R.sub.13 and R.sub.14 are independently selected from the group consisting of hydrogen, hydroxy, halogen, amino, lower alkyl, lower alkoxy, lower alkylthio, methylenedioxy, or ethylenedioxy. The compounds of the present invention selectively inhibit .alpha..sub.2 -adrenergic receptors as well as inhibit the uptake of biogenic amines and are thus useful in the treatment of certain cardiovascular and psychiatric disorders.

  本发明提供了以下结构的化合物##STR1##或其药学上可接受的盐，其中R.sub.1从氢、卤素、较低的烷基、较低的烷氧基或硫代烷氧基中选择；而R.sub.2是较低的烷氧基；或者R.sub.1和R.sub.2一起形成一个亚甲二氧基或乙二氧基环；R.sub.3和R.sub.4独立地从氢、羟基、较低的烷基、较低的烷氧基、较低的烷硫基、(较低的烷基)氨基、(较低的烷基磺酰基)氨基和卤素中选择；而R.sub.7从2-或3-噻吩基、2-或3-呋喃基和##STR2##中选择，其中R.sub.13和R.sub.14独立地从氢、羟基、卤素、氨基、较低的烷基、较低的烷氧基、较低的烷硫基、亚甲二氧基或乙二氧基中选择。本发明的化合物选择性地抑制α2-肾上腺素受体，并抑制生物胺的摄取，因此在治疗某些心血管和精神疾病方面具有用处。
• Biogenic amine uptake inhibitors
  申请人：Abbott Laboratories

  公开号：US05180733A1

  公开（公告）日：1993-01-19

  Compounds of the formula: ##STR1## or a pharmaceutically acceptable salt thereof, wherein M is 0, 1 or 2 and n is 0 or 1; R.sup.1 is hydrogen or lower alkyl; R.sup.2 is C.sub.1 -C.sub.6 -alkyl substituted with a heterocyclic group or C.sub.7 -C.sub.16 -arylalkyl, wherein the aryl group is unsubstituted or substituted with from one to three non-hydrogen members independently selected from the group consisting of halogen, C.sub.1 -C.sub.6 -alkyl, halo-C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkoxy, hydroxy, amino and C.sub.1 -C.sub.6 -alkylamino; R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are independently selected from the group consisting of hydrogen, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkyl, halogen, and halo-C.sub.1 -C.sub.6 -alkyl, or any two of R.sup.3, R.sup.4, R.sup.5 and R.sup.6 taken together form a methylenedioxy group; and R.sup.7 is hydrogen or C.sub.1 -C.sub.6 -alkyl. These compounds are useful as inhibitors of the neuronal uptake of biogenic amines and for the treatment of affective disorders, such as, for example, depression.

  该公式化合物为：##STR1##或其药学上可接受的盐，其中M为0、1或2，n为0或1；R.sup.1为氢或较低的烷基；R.sup.2为C.sub.1 -C.sub.6 -烷基，其上取代有杂环基团或C.sub.7 -C.sub.16 -芳基烷基，其中芳基未取代或取代有1至3个非氢成员，独立选择自卤素、C.sub.1 -C.sub.6 -烷基、卤代C.sub.1 -C.sub.6 -烷基、C.sub.1 -C.sub.6 -烷氧基、羟基、氨基和C.sub.1 -C.sub.6 -烷基氨基；R.sup.3、R.sup.4、R.sup.5和R.sup.6分别选自氢、C.sub.1 -C.sub.6 -烷氧基、C.sub.1 -C.sub.6 -烷基、卤素和卤代C.sub.1 -C.sub.6 -烷基的群，或R.sup.3、R.sup.4、R.sup.5和R.sup.6中的任意两个一起形成亚甲二氧基基团；R.sup.7为氢或C.sub.1 -C.sub.6 -烷基。这些化合物可用作生物胺神经元摄取抑制剂，用于治疗情感障碍，例如抑郁症。
• Biogentic amine uptake inhibitors
  申请人：Abbott Laboratories

  公开号：US05248677A1

  公开（公告）日：1993-09-28

  Compounds of the formula: ##STR1## or a pharmaceutically acceptable salt thereof, wherein m is 0, 1 or 2 and n is 0 or 1; R.sup.1 is hydrogen or lower alkyl; R.sup.2 is C.sub.1 -C.sub.6 -alkyl substituted with a heterocyclic group or C.sub.7 -C.sub.16 -arylalkyl, wherein the aryl group is unsubstituted or substituted with from one to three non-hydrogen members independently selected from the group consisting of halogen, C.sub.1 -C.sub.6 -alkyl, halo-C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkoxy, hydroxy, amino and C.sub.1 -C.sub.6 -alkylamino; R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are independently selected from the group consisting of hydrogen, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkyl, halogen, and halo-C.sub.1 -C.sub.6 -alkyl, or any two of R.sup.3, R.sup.4, R.sup.5 and R.sup.6 taken together form a methylenedioxy group; and R.sup.7 is hydrogen or C.sub.1 -C.sub.6 -alkyl. These compounds are useful as inhibitors of the neuronal uptake of biogenic amines and for the treatment of affective disorders, such as, for example, depression.

  该式化合物为：##STR1## 或其药用可接受的盐，其中m为0、1或2，n为0或1；R.sup.1为氢或较低的烷基；R.sup.2为C.sub.1-C.sub.6-烷基，其上取代有杂环基团或C.sub.7-C.sub.16-芳基烷基，其中芳基未取代或取代有1至3个非氢成员，独立选自卤素、C.sub.1-C.sub.6-烷基、卤代C.sub.1-C.sub.6-烷基、C.sub.1-C.sub.6-氧烷基、羟基、氨基和C.sub.1-C.sub.6-烷基氨基；R.sup.3、R.sup.4、R.sup.5和R.sup.6独立选自氢、C.sub.1-C.sub.6-氧烷基、C.sub.1-C.sub.6-烷基、卤素和卤代C.sub.1-C.sub.6-烷基，或R.sup.3、R.sup.4、R.sup.5和R.sup.6中的任意两个组成亚甲二氧基基团；R.sup.7为氢或C.sub.1-C.sub.6-烷基。这些化合物可用作生物胺神经元摄取抑制剂，用于治疗情感障碍，例如抑郁症。